What do systematic reviews say?

Autologous myeloablative selective HSCT vs cyclophosphamide

Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

• Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
  RR 1.43 [0.99, 2.08]
  1 study · 71 participants
  Moderate

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

• Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Low

Autologous non‐myeloablative selective HSCT vs cyclophosphamide

Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).

• Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
  RR 1.7 [1.2, 2.3]
  1 study · 156 participants
  Moderate

Rituximab vs cyclophosphamide

Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.11 [0.72, 1.71]
  2 studies · 241 participants
  Moderate

Mycophenolate mofetil vs cyclophosphamide

Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.25
  1 study · 140 participants
  Low

Azathioprine vs cyclophosphamide

Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.18 [0.45, 3.07]
  1 study · 144 participants
  Moderate

Calcineurin inhibitor vs IV cyclophosphamide

Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.49 [0.16, 1.56]
  1 study · 131 participants
  Moderate

Calcineurin inhibitor vs IV cyclophosphamide

Calcineurin inhibitor probably leads to lower adverse events: treatment failure at 6 months (non response, serious… compared with IV cyclophosphamide (moderate certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.32 [0.18, 0.58]
  1 study · 124 participants
  Moderate